Compare $BOLT vs $LGVN | Chartloom

Compare

$BOLT vs $LGVN

Bolt Biotherapeutics Inc · Longeveron Inc

BOLT

Bolt Biotherapeutics Inc

LGVN

Longeveron Inc

Compare $BOLT vs $LGVN

Comparing Bolt Biotherapeutics Inc and Longeveron Inc

BOLTBolt Biotherapeutics Inc

LGVNLongeveron Inc

BOLTBolt Biotherapeutics Inc

Market cap

$8M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

12.8%

YTD performance

-29.0%

52W performance

-35.8%

FCF yield

-399.6%

LGVNLongeveron Inc

Market cap

$78M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

64.70x

Rev growth (TTM)

-42.7%

YTD performance

-58.2%

52W performance

-73.3%

FCF yield

-26.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BOLT

LGVN

Detailed metrics comparison

BOLT

Bolt Biotherapeutics Inc

LGVN

Longeveron Inc

Market Cap

BOLT$8M

LGVN$78M

Enterprise Value

BOLT$-5M

LGVN$68M

Price

BOLT$4.11

LGVN$2.48

P/E Ratio

BOLTN/A

LGVNN/A

P/S Ratio

BOLT1.68x

LGVN66.02x

EV/Sales

BOLT-1.06x

LGVN57.53x

EV/EBITDA

BOLT0.00x

LGVN0.00x

P/B Ratio

BOLT0.53x

LGVN0.79x

P/FCF Ratio

BOLTN/A

LGVNN/A

EV/FCF

BOLT0.16x

LGVN-3.30x

PEG Ratio

BOLTN/A

LGVNN/A

Forward P/E (NTM)

BOLTN/A

LGVNN/A

Forward P/S (NTM)

BOLTN/A

LGVN64.70x

Revenue (TTM)

BOLT$5M

LGVN$1M

Revenue Growth (YoY)

BOLT12.8%

LGVN-42.7%

Forward Rev Growth

BOLT1650.0%

LGVN398.7%

Gross Margin (TTM)

BOLT0.0%

LGVN69.8%

Operating Margin (TTM)

BOLT0.0%

LGVN0.0%

EBITDA Margin (TTM)

BOLT-586.3%

LGVN-1907.3%

Net Margin (TTM)

BOLT-611.5%

LGVN-1977.6%

FCF Margin (TTM)

BOLT-671.0%

LGVN-1742.1%

Net Income (TTM)

BOLT$-29M

LGVN$-23M

FCF (TTM)

BOLT$-32M

LGVN$-21M

EPS (TTM)

BOLT-$17.00

LGVN-$7.48

ROE (TTM)

BOLT-12623.0%

LGVN-22319.0%

ROA (TTM)

BOLT-5470.0%

LGVN-15020.0%

ROIC (TTM)

BOLT-12623.0%

LGVN-22319.0%

Cash

BOLT$13M

LGVN$10M

Debt

BOLT$0

LGVN$0

Net Cash/Debt

BOLT$13M

LGVN$10M

Current Ratio (TTM)

BOLT2.61x

LGVN2.63x

Quick Ratio (TTM)

BOLT2.26x

LGVN2.35x

Debt/Equity (TTM)

BOLT0.00x

LGVN0.00x

Debt/Assets (TTM)

BOLT0.0%

LGVN0.0%

Interest Coverage (TTM)

BOLTN/A

LGVNN/A

Net Debt/EBITDA (TTM)

BOLT0.00x

LGVN0.00x

Beta

BOLT0.97

LGVN0.85

52W Performance

BOLT-35.8%

LGVN-73.3%

YTD Performance

BOLT-29.0%

LGVN-58.2%

% from 52W High

BOLT-42.9%

LGVN-79.8%

% from 52W Low

BOLT32.6%

LGVN7.8%

Asset Turnover (TTM)

BOLT0.09x

LGVN0.08x

FCF Yield (TTM)

BOLT-399.6%

LGVN-26.4%

Earnings Yield (TTM)

BOLT-364.2%

LGVN-30.0%

Dividend Yield (TTM)

BOLTN/A

LGVNN/A

Rule of 40

BOLT-658.2

LGVN-1,784.9

EV/GP/RG

BOLTN/A

LGVN40.37

Ticker research

View BOLT research View LGVN research

Metric	BOLT Bolt Biotherapeutics Inc	LGVN Longeveron Inc
Market & Valuation
Market Cap	$8M	$78M
Enterprise Value	$-5M	$68M
Price	$4.11	$2.48
P/E Ratio	N/A	N/A
P/S Ratio	1.68x	66.02x
EV/Sales	-1.06x	57.53x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.53x	0.79x
P/FCF Ratio	N/A	N/A
EV/FCF	0.16x	-3.30x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	64.70x
Revenue & Growth
Revenue (TTM)	$5M	$1M
Revenue Growth (YoY)	12.8%	-42.7%
Forward Rev Growth	1650.0%	398.7%
Profitability
Gross Margin (TTM)	0.0%	69.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-586.3%	-1907.3%
Net Margin (TTM)	-611.5%	-1977.6%
FCF Margin (TTM)	-671.0%	-1742.1%
Net Income (TTM)	$-29M	$-23M
FCF (TTM)	$-32M	$-21M
EPS (TTM)	-$17.00	-$7.48
ROE (TTM)	-12623.0%	-22319.0%
ROA (TTM)	-5470.0%	-15020.0%
ROIC (TTM)	-12623.0%	-22319.0%
Financial Health
Cash	$13M	$10M
Debt	$0	$0
Net Cash/Debt	$13M	$10M
Current Ratio (TTM)	2.61x	2.63x
Quick Ratio (TTM)	2.26x	2.35x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.97	0.85
52W Performance	-35.8%	-73.3%
YTD Performance	-29.0%	-58.2%
% from 52W High	-42.9%	-79.8%
% from 52W Low	32.6%	7.8%
Efficiency & Yields
Asset Turnover (TTM)	0.09x	0.08x
FCF Yield (TTM)	-399.6%	-26.4%
Earnings Yield (TTM)	-364.2%	-30.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-658.2	-1,784.9
EV/GP/RG	N/A	40.37
Ticker research	View BOLT research	View LGVN research

Valuation

P/S Ratio

BOLT

1.68x

LGVN

66.02x

EV/FCF

LGVN

-3.30x

BOLT

0.16x

Growth & revenue

Revenue Growth TTM

BOLT

12.8%

LGVN

-42.7%

Forward Revenue Growth

BOLT

1650.0%

LGVN

398.7%

Profitability & performance

Gross Margin

LGVN

69.8%

BOLT

0.0%

ROE

BOLT

-12623.0%

LGVN

-22319.0%

FCF Yield %

LGVN

-26.4%

BOLT

-399.6%

52-Week Performance

BOLT

-35.8%

LGVN

-73.3%

Detailed metrics comparison

BOLT

Bolt Biotherapeutics Inc

LGVN

Longeveron Inc

Market Cap

BOLT$8M

LGVN$78M

Enterprise Value

BOLT$-5M

LGVN$68M

Price

BOLT$4.11

LGVN$2.48

P/E Ratio

BOLTN/A

LGVNN/A

P/S Ratio

BOLT1.68x

LGVN66.02x

EV/Sales

BOLT-1.06x

LGVN57.53x

EV/EBITDA

BOLT0.00x

LGVN0.00x

P/B Ratio

BOLT0.53x

LGVN0.79x

P/FCF Ratio

BOLTN/A

LGVNN/A

EV/FCF

BOLT0.16x

LGVN-3.30x

PEG Ratio

BOLTN/A

LGVNN/A

Forward P/E (NTM)

BOLTN/A

LGVNN/A

Forward P/S (NTM)

BOLTN/A

LGVN64.70x

Revenue (TTM)

BOLT$5M

LGVN$1M

Revenue Growth (YoY)

BOLT12.8%

LGVN-42.7%

Forward Rev Growth

BOLT1650.0%

LGVN398.7%

Gross Margin (TTM)

BOLT0.0%

LGVN69.8%

Operating Margin (TTM)

BOLT0.0%

LGVN0.0%

EBITDA Margin (TTM)

BOLT-586.3%

LGVN-1907.3%

Net Margin (TTM)

BOLT-611.5%

LGVN-1977.6%

FCF Margin (TTM)

BOLT-671.0%

LGVN-1742.1%

Net Income (TTM)

BOLT$-29M

LGVN$-23M

FCF (TTM)

BOLT$-32M

LGVN$-21M

EPS (TTM)

BOLT-$17.00

LGVN-$7.48

ROE (TTM)

BOLT-12623.0%

LGVN-22319.0%

ROA (TTM)

BOLT-5470.0%

LGVN-15020.0%

ROIC (TTM)

BOLT-12623.0%

LGVN-22319.0%

Cash

BOLT$13M

LGVN$10M

Debt

BOLT$0

LGVN$0

Net Cash/Debt

BOLT$13M

LGVN$10M

Current Ratio (TTM)

BOLT2.61x

LGVN2.63x

Quick Ratio (TTM)

BOLT2.26x

LGVN2.35x

Debt/Equity (TTM)

BOLT0.00x

LGVN0.00x

Debt/Assets (TTM)

BOLT0.0%

LGVN0.0%

Interest Coverage (TTM)

BOLTN/A

LGVNN/A

Net Debt/EBITDA (TTM)

BOLT0.00x

LGVN0.00x

Beta

BOLT0.97

LGVN0.85

52W Performance

BOLT-35.8%

LGVN-73.3%

YTD Performance

BOLT-29.0%

LGVN-58.2%

% from 52W High

BOLT-42.9%

LGVN-79.8%

% from 52W Low

BOLT32.6%

LGVN7.8%

Asset Turnover (TTM)

BOLT0.09x

LGVN0.08x

FCF Yield (TTM)

BOLT-399.6%

LGVN-26.4%

Earnings Yield (TTM)

BOLT-364.2%

LGVN-30.0%

Dividend Yield (TTM)

BOLTN/A

LGVNN/A

Rule of 40

BOLT-658.2

LGVN-1,784.9

EV/GP/RG

BOLTN/A

LGVN40.37

Ticker research

View BOLT research View LGVN research

Metric	BOLT Bolt Biotherapeutics Inc	LGVN Longeveron Inc
Market & Valuation
Market Cap	$8M	$78M
Enterprise Value	$-5M	$68M
Price	$4.11	$2.48
P/E Ratio	N/A	N/A
P/S Ratio	1.68x	66.02x
EV/Sales	-1.06x	57.53x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.53x	0.79x
P/FCF Ratio	N/A	N/A
EV/FCF	0.16x	-3.30x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	64.70x
Revenue & Growth
Revenue (TTM)	$5M	$1M
Revenue Growth (YoY)	12.8%	-42.7%
Forward Rev Growth	1650.0%	398.7%
Profitability
Gross Margin (TTM)	0.0%	69.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-586.3%	-1907.3%
Net Margin (TTM)	-611.5%	-1977.6%
FCF Margin (TTM)	-671.0%	-1742.1%
Net Income (TTM)	$-29M	$-23M
FCF (TTM)	$-32M	$-21M
EPS (TTM)	-$17.00	-$7.48
ROE (TTM)	-12623.0%	-22319.0%
ROA (TTM)	-5470.0%	-15020.0%
ROIC (TTM)	-12623.0%	-22319.0%
Financial Health
Cash	$13M	$10M
Debt	$0	$0
Net Cash/Debt	$13M	$10M
Current Ratio (TTM)	2.61x	2.63x
Quick Ratio (TTM)	2.26x	2.35x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.97	0.85
52W Performance	-35.8%	-73.3%
YTD Performance	-29.0%	-58.2%
% from 52W High	-42.9%	-79.8%
% from 52W Low	32.6%	7.8%
Efficiency & Yields
Asset Turnover (TTM)	0.09x	0.08x
FCF Yield (TTM)	-399.6%	-26.4%
Earnings Yield (TTM)	-364.2%	-30.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-658.2	-1,784.9
EV/GP/RG	N/A	40.37
Ticker research	View BOLT research	View LGVN research